{
    "ticker": "DNLI",
    "name": "Denali Therapeutics Inc.",
    "description": "Denali Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, Denali is committed to addressing the unmet needs of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The company utilizes its proprietary drug delivery platform, which includes the Transport Vehicle technology, to enhance the delivery of therapeutics across the blood-brain barrier. Denali's pipeline includes both small molecule and biologic candidates designed to target various aspects of neurodegeneration. The company aims to provide transformative treatment options to improve the lives of patients and their families. With a strong emphasis on scientific research and collaboration, Denali Therapeutics is advancing its mission of making a meaningful impact in the field of neurology and developing a new generation of therapies that can slow or halt the progression of neurodegenerative diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.denalitherapeutics.com",
    "ceo": "Ryan Watts",
    "social_media": {
        "twitter": "https://twitter.com/DenaliThera",
        "linkedin": "https://www.linkedin.com/company/denali-therapeutics/"
    },
    "investor_relations": "https://investors.denalitherapeutics.com",
    "key_executives": [
        {
            "name": "Ryan Watts",
            "position": "CEO"
        },
        {
            "name": "Dale Schenk",
            "position": "President"
        },
        {
            "name": "Lynn H. Goldstein",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "DNL-151",
                "DNL-203"
            ]
        }
    ],
    "seo": {
        "meta_title": "Denali Therapeutics Inc. | Innovating Neurodegenerative Disease Therapies",
        "meta_description": "Explore Denali Therapeutics Inc., a biotechnology leader focused on developing novel therapies for neurodegenerative diseases through innovative drug delivery technologies.",
        "keywords": [
            "Denali Therapeutics",
            "Neurodegenerative Diseases",
            "Biotechnology",
            "Alzheimer's Disease",
            "Parkinson's Disease",
            "Blood-Brain Barrier"
        ]
    },
    "faq": [
        {
            "question": "What is Denali Therapeutics known for?",
            "answer": "Denali Therapeutics is known for developing innovative therapies for neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of Denali Therapeutics?",
            "answer": "Ryan Watts is the CEO of Denali Therapeutics Inc."
        },
        {
            "question": "Where is Denali Therapeutics headquartered?",
            "answer": "Denali Therapeutics is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Denali's main products?",
            "answer": "Denali's main product candidates include DNL-151 and DNL-203, targeting neurodegenerative conditions."
        },
        {
            "question": "When was Denali Therapeutics founded?",
            "answer": "Denali Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "BIIB",
        "ABBV",
        "SNY",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "CELG"
    ]
}